We can state the hypothesis that the potential FGF19-resistance is not primarily due to a lowered Fgfr4 and Klb expression in muscles but potentially by impaired signal transduction Therefore, our study is important to validate the proof of concept of the efficacy of FGF19 treatment in uremic context and in CKD patients. This evidence concerns the gene KLB and chronic kidney disease.